Patents by Inventor Andreas Kindmark

Andreas Kindmark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SNPS IN THE APOB GENE AND SUSCEPTIBILITY TO INCREASED LEVELS OF ALAT FOLLOWING XIMELAGATRAN ADMINISTRATION
    Publication number: 20090227559
    Abstract: This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between certain SNPs in the apoB gene and susceptibility to increased levels of alanine aminotransferase (ALAT) following ximelagatran administration. Thus, this invention relates to methods for predicting susceptibility to elevated ALAT following ximelagatran administration and to methods for administering a pharmaceutically useful anticoagulant drug to certain suitable patients.
    Type: Application
    Filed: October 3, 2006
    Publication date: September 10, 2009
    Applicant: AstraZeneca AB
    Inventors: Olof Bengtsson, Ellen Brown, Stefan Carlsson, Neil James Gibson, Ansar Jawaid, Andreas Kindmark, Ruth Eleanor March
  • POLYMORPHISMS IN MGST3 ARE ASSOCIATED WITH ELEVATED ALAT LEVELS AFTER XIMELAGATRAN TREATMENT
    Publication number: 20090054394
    Abstract: This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between certain SNPs in the MGST3 gene and susceptibility to increased levels of alanine aminotransferase (ALAT) following ximelagatran administration. Thus, this invention relates to methods for predicting susceptibility to elevated ALAT following ximelagatran administration and to methods for administering a pharmaceutically useful anticoagulant drug to certain suitable patients.
    Type: Application
    Filed: October 3, 2006
    Publication date: February 26, 2009
    Inventors: Olof Bengtsson, Ellen Brown, Stefan Carlsson, Neil James Gibson, Ansar Jawaid, Andreas Kindmark, Ruth Eleanor March
  • ASSOCIATION BETWEEN HLA-DRBI*07 ALLELE AND SUSCEPTIBILY TO INCREASED LEVELS OF ALAT FOLLOWING XIMELAGATRAN ADMINISTRATION
    Publication number: 20090036424
    Abstract: This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between HLA-DRB1*07 allele and susceptibility to increased levels of alanine aminotransferase (ALAT) following ximelagatran administration. Thus, this invention relates to methods for predicting susceptibility to elevated ALAT following ximelagatran administration and to methods for administering a pharmaceutically useful anticoagulant drug to certain suitable patients.
    Type: Application
    Filed: October 3, 2006
    Publication date: February 5, 2009
    Applicant: AstraZeneca AB
    Inventors: Olof Bengtsson, Ellen Brown, Stefan Carlsson, Neil James Gibson, Ansar Jawaid, Andreas Kindmark, Ruth Eleanor March
  • POLYMORPHISMS IN PON1 ARE ASSOCIATED WITH ELEVATED ALANINE AMINOTRANSFERASE LEVELS AFTER XIMELAGATRAN OR TACRINE ADMINISTRATION
    Publication number: 20090029367
    Abstract: This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between certain SNPs in the PON1 gene and susceptibility to increased levels of alanine aminotransferase (ALAT) following ximelagatran or tacrine administration. Thus, this invention relates to methods for predicting susceptibility to elevated ALAT following ximelagatran or tacrine administration and to methods for administering a pharmaceutically useful anticoagulant drug to certain suitable patients.
    Type: Application
    Filed: October 3, 2006
    Publication date: January 29, 2009
    Applicant: AstraZeneca AB
    Inventors: Olof Bengtsson, Ellen Brown, Stefan Carlsson, Neil James Gibson, Ansar Jawaid, Andreas Kindmark, Ruth Eleanor March